Streetbeat News

Regulatory

CLVR

Clever Leaves Holdings Inc. (NASDAQ:CLVR) has received Australian GMP certification for its Colombian facilities from the TGA, allowing it to manufacture cannabis products for the Australian medical marijuana market. This certification is crucial for ensuring product quality and safety, and it represents a significant milestone for the company. Despite this positive development, CLVR shares traded slightly lower at $2.06 per share in the pre-market session on Wednesday.

Portfolio Pulse from Jelena Martinovic

January 03, 2024 | 3:04 pm

AMD

NVDA

Nvidia (NVDA) and AMD (AMD) stocks are trading lower due to the Netherlands' restrictions on exporting specific lithography systems to China, impacting chip production. Despite a positive market outlook for 2024 with anticipated interest rate cuts, there's skepticism about the future performance of major tech companies, including Nvidia and AMD. DA Davidson analyst Gil Luria initiated coverage on Nvidia with a Neutral rating and a price target of $410.

Portfolio Pulse from Anusuya Lahiri

January 03, 2024 | 2:50 pm

DSNKY

ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares dropped after announcing a $125 million amendment to its collaboration with Daiichi Sankyo Europe GmbH. The amendment includes a $100 million payment to Esperion in mid-January and an additional $25 million following EMA's decision on NILEMDO and NUSTENDI. The legal action in the U.S. will be dismissed, and DSE will control EMA regulatory communications for the drugs.

Portfolio Pulse from Nabaparna Bhattacharya

January 03, 2024 | 2:47 pm

USO

Reuters reports an OPEC statement affirming that cooperation and dialogue within OPEC+ will persist, benefiting producers, consumers, investors, and the global economy.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:43 pm

USO

OPEC+ has played a significant role in stabilizing the global economy and ensuring market stability through its efforts over the past years, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:43 pm

USO

OPEC+ countries have re-affirmed their commitment to unity, full cohesion, and market stability through the Declaration of Cooperation, according to Reuters. This move is aimed at ensuring a balanced and stable oil market, which is critical for both producers and consumers globally. The collaboration among the member countries is expected to continue to play a significant role in the global oil market dynamics.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:42 pm

KSCP

Knightscope, Inc. (NASDAQ:KSCP) has received Authority to Operate (ATO) from FedRAMP, sponsored by the U.S. Department of Veterans Affairs. This allows Knightscope to be listed on the FedRAMP Marketplace as an approved provider for federal agencies and begin deployment for the VA contract. The company's 2024 Roadmap includes growth, margin improvements, acquisitions, and pre-orders for the new K7 in 2025.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:32 pm

AAPL

ADBE

AMZN

GOOG

MSFT

techUK, representing companies like Apple, Google, and Microsoft, opposes UK's proposed surveillance laws, fearing data security threats and legal conflicts. The group, which includes Apple, Alphabet's Google, Microsoft, Adobe, and Amazon, seeks to discuss the Investigatory Powers Act changes that could undermine encryption and impact tech investments in the UK. Apple has previously resisted such laws and threatened to withdraw iMessage and FaceTime over encryption issues.

Portfolio Pulse from Rounak Jain

January 03, 2024 | 2:21 pm

PFE

Health Canada has approved Pfizer Canada's gene therapy BEQVEZ for adults with hemophilia B. The approval is based on the Phase 3 BENEGENE-2 study, which showed potential in reducing the burden of frequent infusions. Over 700 individuals in Canada are affected by hemophilia B. The Canadian Hemophilia Society welcomed the approval and is working to make the therapy accessible across Canada.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:14 pm

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) has been granted a U.S. patent for a malaria vaccine that covers both prevention and treatment. The patent, No. 11,857,611, is for a vaccine using GeoVax's MVA vector expressing Plasmodium antigens. This vaccine aims to induce an immune response targeting multiple stages of the malaria parasite's life cycle. The issuance of this patent comes as the first cases of locally transmitted malaria have been reported in the U.S. in 20 years. GeoVax's President and CEO, David Dodd, emphasized the company's commitment to public health and the development of vaccines against global threats like malaria.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 2:01 pm